INTRODUCTION

9
Zika virus (ZIKV) is an arthropod-borne virus, transmitted by Aedes mosquitoes, 3 0 that belongs to the Flavivirius genus, which also includes other pathogens such as West In utero exposure to ZIKV might lead to microcephaly and other developmental Zika syndrome (Brasil et al., 2016; Martines et al., 2016; Mlakar et al., 2016 ; Oliveira Melo confirmed of ZIKV-related microcephaly (http://portalsaude.saude.gov.br). microcephaly (Brasil et al., 2016; Calvet et al., 2016; Martines et al., 2016; Mlakar et al., NSCs pool (Gilmore and Walsh, 2013) . In order to evaluate if chloroquine could protect 1 0 3 these cells from ZIKV infection, they were exposed to up to 50µM chloroquine for 4 days.
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Chloroquine treatment decreases 60% of the number of ZIKV-infected hNSC cells and neurospheres and induced to differentiate into neurons. Our group showed that ZIKV phenotype ( Fig. 4A-C) . ZIKV infection decreased when 12.5 µM chloroquine was added to 1 1 7 the medium, as evaluated by 4G2 staining (Fig. 4D-F) . Microcephaly cases and neurological disorders have only been associated to the 40-fold reduction in ZIKV particle production, regardless the viral lineage used (FIG. S1) .
Chloroquine inhibits early stages of ZIKV infection 1 2 8
Inhibition of viral infection mediated by chloroquine can occur in both early and cells. However, chloroquine added at 24 hpi had no effect on viral production (FIG. 5A).
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These results were confirmed by quantification of ZIKV infectious particles release after Here we demonstrate that chloroquine decreases the number of ZIKV-infected cells of cells from ZIKV-induced death, was 9.82-14.2 µM depending on cell model and 50% of EC50 are lower than those obtained for DENV inhibition (around 25 µM) and HIV A clinical trial of chloroquine administration to DENV-infected patients during 1 6 0 three days showed that 60% of the patients in the chloroquine treated group reported feeling 1 6 1 less pain and showed improvement in the performance of daily chores during treatment. Chloroquine is widely distributed to body tissues as well as its analogue µM when a daily intake of 500 mg was prescribed to arthritis patients (Mackenzie, 1983) . Chloroquine is able to cross the placental barrier and is supposed to reach similar concentrations on maternal and fetal plasma (Law et al., 2008) . Concentrations needed to approval as a therapeutic agent against ZIKV should be faster than new compounds.
The use of chloroquine during pregnancy was evaluated and when prophylactic 1 7 5 doses of chloroquine were administered for malaria (400 mg/week), no increment in birth 1 7 6 defects was observed (Wolfe and Cordero, 1985) . Higher concentrations (250 mg to 500 1 7 7 mg/day) are administered to pregnant women who have severe diseases, such as lupus or toxicity or death could not be discarded as consequence of disease itself since, in most stages of ZIKV cycle might also be affected, although we cannot eliminate a potential 1 9 2 impact on a new cycle of infection. The proposed mechanism for chloroquine action on later stages of viral replication relates to the alteration of post-translational modifications in the trans-golgi network. Chloroquine treatment impairs Flavivirus prM cleavage, which prevents virus maturation 1 9 6 and, consequently, infectivity (Randolph et al., 1990; Zybert et al., 2008) . For HIV-1,
chloroquine inhibits the glycosylation of the gp120 protein, responsible for cell attachment flavivirus envelope protein has yet to be addressed. Recent studies showed that neural stem cells are highly permissive for ZIKV groundbreaking feature of this compound, as it would be prescribed to women at areas. This would decrease the chances of infection and thus fetal damage, especially to the 2 2 0 developing brain.
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Altogether, our results suggest that chloroquine activity against ZIKV should 2 2 2 immediately be evaluated in vivo and hopefully it will mitigate the devastating brain neurospheres were infected with ZIKV MR766 and treated with chloroquine for 3 days. Neurospheres were analyzed by phase contrast microscopy (A-C) and triple stained for 2 6 6 envelope viral protein (green), Map-2 (red), a neuron-specific protein, and DAPI (blue) (D-2 6 7 F). were quantified. (CC50/EC50). Data are represented as mean ± SD. or tables, analyzed the data and wrote the manuscript; PG designed and performed
